Merck's Welireg scores FDA nod in cancers spurred by rare disease—and its label is broader than expected

Belzutifan, one of the most lucrative assets Merck picked up through its 2019 Peloton buy, snared its first FDA approval Friday for patients with the rare disorder known as von Hippel-Lindau (VHL) disease.